Regarding therapeutic interventions, insulin can delay the onset and progression of DKD by affording glycemic control; however, in some cases, insulin monotherapy is insufficient to maintain blood glucose within the therapeutic target, requiring adjuvant therapeutic interventions10–12. This evidence concerns the gene INS and diabetic kidney disease.